{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T18:43:03Z","timestamp":1792694583777,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,1,23]],"date-time":"2022-01-23T00:00:00Z","timestamp":1642896000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,23]],"date-time":"2022-01-23T00:00:00Z","timestamp":1642896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100002261","name":"\u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u0438\u0439 \u0424\u043e\u043d\u0434 \u0424\u0443\u043d\u0434\u0430\u043c\u0435\u043d\u0442\u0430\u043b\u044c\u043d\u044b\u0445 \u0418\u0441\u0441\u043b\u0435\u0434\u043e\u0432\u0430\u043d\u0438\u0439","doi-asserted-by":"publisher","award":["20-015-00116"],"award-info":[{"award-number":["20-015-00116"]}],"id":[{"id":"10.13039\/501100002261","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s12035-021-02688-0","type":"journal-article","created":{"date-parts":[[2022,1,23]],"date-time":"2022-01-23T00:04:21Z","timestamp":1642896261000},"page":"2277-2287","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Impaired Sphingolipid Hydrolase Activities in Dementia with Lewy Bodies and Multiple System Atrophy"],"prefix":"10.1007","volume":"59","author":[{"given":"T. S.","family":"Usenko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. A.","family":"Senkevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. I.","family":"Bezrukova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. V.","family":"Baydakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. S.","family":"Basharova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. S.","family":"Zhuravlev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. V.","family":"Gracheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. V.","family":"Kudrevatykh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. V.","family":"Miliukhina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. V.","family":"Krasakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. A.","family":"Khublarova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. V.","family":"Fursova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. V.","family":"Zakharov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. A.","family":"Timofeeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. A.","family":"Irishina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. I.","family":"Palchikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. M.","family":"Zalutskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. K.","family":"Emelyanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Y.","family":"Zakharova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. N.","family":"Pchelina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,23]]},"reference":[{"key":"2688_CR1","doi-asserted-by":"publisher","unstructured":"Coon EA, Singer W (2020) Synucleinopathies. Contin Lifelong Learn Neurol 26:72\u201392. https:\/\/doi.org\/10.1212\/CON.0000000000000819","DOI":"10.1212\/CON.0000000000000819"},{"key":"2688_CR2","doi-asserted-by":"publisher","unstructured":"Lee HJ, Ricarte D, Ortiz D, Lee SJ (2019) Models of multiple system atrophy. Exp Mol Med 51:. https:\/\/doi.org\/10.1038\/s12276-019-0346-8","DOI":"10.1038\/s12276-019-0346-8"},{"key":"2688_CR3","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/jnc.14707","volume":"150","author":"AT Marvian","year":"2019","unstructured":"Marvian AT, Koss DJ, Aliakbari F et al (2019) In vitro models of synucleinopathies: informing on molecular mechanisms and protective strategies. J Neurochem 150:535\u2013565. https:\/\/doi.org\/10.1111\/jnc.14707","journal-title":"J Neurochem"},{"key":"2688_CR4","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.1073\/pnas.1514005113","volume":"113","author":"F Zunke","year":"2016","unstructured":"Zunke F, Andresen L, Wesseler S et al (2016) Characterization of the complex formed by \u03b2-glucocerebrosidase and the lysosomal integral membrane protein type-2. Proc Natl Acad Sci U S A 113:3791\u20133796. https:\/\/doi.org\/10.1073\/pnas.1514005113","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2688_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.cca.2019.03.1627","volume":"495","author":"S Paciotti","year":"2019","unstructured":"Paciotti S, Gatticchi L, Beccari T, Parnetti L (2019) Lysosomal enzyme activities as possible CSF biomarkers of synucleinopathies. Clin Chim Acta 495:13\u201324. https:\/\/doi.org\/10.1016\/j.cca.2019.03.1627","journal-title":"Clin Chim Acta"},{"key":"2688_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/cshperspect.a004804","volume":"3","author":"H Schulze","year":"2011","unstructured":"Schulze H, Sandhoff K (2011) Lysosomal lipid storage diseases. Cold Spring Harb Perspect Biol 3:1\u201319. https:\/\/doi.org\/10.1101\/cshperspect.a004804","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2688_CR7","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1007\/s11910-010-0102-x","volume":"10","author":"A Velayati","year":"2010","unstructured":"Velayati A, Yu WH, Sidransky E (2010) The role of glucocerebrosidase mutations in parkinson disease and Lewy body disorders. Curr Neurol Neurosci Rep 10:190\u2013198","journal-title":"Curr Neurol Neurosci Rep"},{"key":"2688_CR8","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1006\/mgme.2001.3201","volume":"73","author":"N Tayebi","year":"2001","unstructured":"Tayebi N, Callahan M, Madike V et al (2001) Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. Mol Genet Metab 73:313\u2013321. https:\/\/doi.org\/10.1006\/mgme.2001.3201","journal-title":"Mol Genet Metab"},{"key":"2688_CR9","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/S1096-7192(03)00071-4","volume":"79","author":"N Tayebi","year":"2003","unstructured":"Tayebi N, Walker J, Stubblefield B et al (2003) Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? Mol Genet Metab 79:104\u2013109. https:\/\/doi.org\/10.1016\/S1096-7192(03)00071-4","journal-title":"Mol Genet Metab"},{"key":"2688_CR10","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","volume":"361","author":"E Sidransky","year":"2009","unstructured":"Sidransky E, Nalls MA, Aasly JO et al (2009) Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease. N Engl J Med 361:1651\u20131661. https:\/\/doi.org\/10.1056\/NEJMoa0901281","journal-title":"N Engl J Med"},{"key":"2688_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2018.06.027","author":"AK Emelyanov","year":"2018","unstructured":"Emelyanov AK, Usenko TS, Tesson C et al (2018) Mutation analysis of Parkinson\u2019s disease genes in a Russian data set. Neurobiol Aging. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2018.06.027","journal-title":"Neurobiol Aging"},{"key":"2688_CR12","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1093\/brain\/awp044","volume":"132","author":"J Neumann","year":"2009","unstructured":"Neumann J, Bras J, Deas E et al (2009) Glucocerebrosidase mutations in clinical and pathologically proven Parkinson\u2019s disease. Brain 132:1783\u20131794. https:\/\/doi.org\/10.1093\/brain\/awp044","journal-title":"Brain"},{"key":"2688_CR13","doi-asserted-by":"publisher","first-page":"2890.e13","DOI":"10.1016\/j.neurobiolaging.2013.06.010","volume":"34","author":"JN Foo","year":"2013","unstructured":"Foo JN, Liany H, Bei JX et al (2013) A rare lysosomal enzyme gene SMPD1 variant (p. R591C) associates with Parkinson\u2019s disease. Neurobiol Aging 34:2890.e13-2890.e15. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2013.06.010","journal-title":"Neurobiol Aging"},{"key":"2688_CR14","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.parkreldis.2015.06.016","volume":"21","author":"E Dagan","year":"2015","unstructured":"Dagan E, Schlesinger I, Ayoub M et al (2015) The contribution of Niemann-Pick SMPD1 mutations to Parkinson disease in Ashkenazi Jews. Park Relat Disord 21:1067\u20131071. https:\/\/doi.org\/10.1016\/j.parkreldis.2015.06.016","journal-title":"Park Relat Disord"},{"key":"2688_CR15","doi-asserted-by":"publisher","unstructured":"Gan-Or Z, Ozelius LJ, Bar-Shira A, et al (2013) The p.L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease. Neurology. https:\/\/doi.org\/10.1212\/WNL.0b013e31828f180e","DOI":"10.1212\/WNL.0b013e31828f180e"},{"key":"2688_CR16","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1093\/brain\/awx285","volume":"140","author":"LA Robak","year":"2017","unstructured":"Robak LA, Jansen IE, van Rooij J et al (2017) Excessive burden of lysosomal storage disorder gene variants in Parkinson\u2019s disease. Brain 140:3191\u20133203. https:\/\/doi.org\/10.1093\/brain\/awx285","journal-title":"Brain"},{"key":"2688_CR17","doi-asserted-by":"publisher","unstructured":"Alcalay RN, Wolf P, Levy OA, et al (2018) Alpha galactosidase A activity in Parkinson\u2019s disease. Neurobiol Dis. https:\/\/doi.org\/10.1016\/j.nbd.2018.01.012","DOI":"10.1016\/j.nbd.2018.01.012"},{"key":"2688_CR18","doi-asserted-by":"publisher","unstructured":"Alcalay RN, Mallett V, Vanderperre B, et al (2019) SMPD1 mutations, activity, and \u03b1-synuclein accumulation in Parkinson\u2019s disease. Mov Disord. https:\/\/doi.org\/10.1002\/mds.27642","DOI":"10.1002\/mds.27642"},{"key":"2688_CR19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.parkreldis.2010.09.009","volume":"17","author":"K Nishioka","year":"2011","unstructured":"Nishioka K, Ross OA, Vilari\u00f1o-G\u00fcell C et al (2011) Glucocerebrosidase mutations in diffuse Lewy body disease. Park Relat Disord 17:55\u201357. https:\/\/doi.org\/10.1016\/j.parkreldis.2010.09.009","journal-title":"Park Relat Disord"},{"key":"2688_CR20","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1007\/s12035-018-1090-0","volume":"56","author":"TE Moors","year":"2019","unstructured":"Moors TE, Paciotti S, Ingrassia A et al (2019) Characterization of brain lysosomal activities in GBA-related and sporadic Parkinson\u2019s disease and dementia with Lewy bodies. Mol Neurobiol 56:1344\u20131355. https:\/\/doi.org\/10.1007\/s12035-018-1090-0","journal-title":"Mol Neurobiol"},{"key":"2688_CR21","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/ana.23614","volume":"72","author":"ME Gegg","year":"2012","unstructured":"Gegg ME, Burke D, Heales SJR et al (2012) Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann Neurol 72:455\u2013463. https:\/\/doi.org\/10.1002\/ana.23614","journal-title":"Ann Neurol"},{"key":"2688_CR22","doi-asserted-by":"publisher","unstructured":"Alcalay RN, Wolf P, Chiang MSR, et al (2020) Longitudinal measurements of glucocerebrosidase activity in Parkinson\u2019s patients. Ann Clin Transl Neurol 1\u201315. https:\/\/doi.org\/10.1002\/acn3.51164","DOI":"10.1002\/acn3.51164"},{"key":"2688_CR23","doi-asserted-by":"publisher","unstructured":"Pchelina S, Emelyanov A, Baydakova G, et al (2017) Oligomeric \u03b1-synuclein and glucocerebrosidase activity levels in GBA-associated Parkinson\u2019s disease. Neurosci Lett. https:\/\/doi.org\/10.1016\/j.neulet.2016.10.039","DOI":"10.1016\/j.neulet.2016.10.039"},{"key":"2688_CR24","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1002\/mds.26433","volume":"30","author":"N Papagiannakis","year":"2015","unstructured":"Papagiannakis N, Xilouri M, Koros C et al (2015) Lysosomal alterations in peripheral blood mononuclear cells of Parkinson\u2019s disease patients. Mov Disord 30:1830\u20131834. https:\/\/doi.org\/10.1002\/mds.26433","journal-title":"Mov Disord"},{"key":"2688_CR25","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3390\/jcm9020594","volume":"9","author":"S Paciotti","year":"2020","unstructured":"Paciotti S, Albi E, Parnetti L, Beccari T (2020) Lysosomal ceramide metabolism disorders: implications in Parkinson\u2019s disease. J Clin Med 9:594. https:\/\/doi.org\/10.3390\/jcm9020594","journal-title":"J Clin Med"},{"key":"2688_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27393","author":"S Pchelina","year":"2018","unstructured":"Pchelina S, Baydakova G, Nikolaev M et al (2018) Blood lysosphingolipids accumulation in patients with parkinson\u2019s disease with glucocerebrosidase 1 mutations. Mov Disord. https:\/\/doi.org\/10.1002\/mds.27393","journal-title":"Mov Disord"},{"key":"2688_CR27","doi-asserted-by":"crossref","unstructured":"Postuma RB, Berg D, Stern M, et al (2015) MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov. Disord.","DOI":"10.1002\/mds.26424"},{"key":"2688_CR28","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","volume":"71","author":"S Gilman","year":"2008","unstructured":"Gilman S, Wenning GK, Low PA et al (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71:670\u2013676. https:\/\/doi.org\/10.1212\/01.wnl.0000324625.00404.15","journal-title":"Neurology"},{"key":"2688_CR29","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith IG, Boeve BF, Dickson DW et al (2017) Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology 89:88\u2013100. https:\/\/doi.org\/10.1212\/WNL.0000000000004058","journal-title":"Neurology"},{"key":"2688_CR30","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1212\/01.wnl.0000176987.47875.28","volume":"65","author":"J Aharon-Peretz","year":"2005","unstructured":"Aharon-Peretz J, Badarny S, Rosenbaum H, Gershoni-Baruch R (2005) Mutations in the glucocerebrosidase gene and Parkinson disease: phenotype-genotype correlation. Neurology 65:1460\u20131461. https:\/\/doi.org\/10.1212\/01.wnl.0000176987.47875.28","journal-title":"Neurology"},{"key":"2688_CR31","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1089\/gtmb.2011.0016","volume":"15","author":"DI Hashad","year":"2011","unstructured":"Hashad DI, Abou-Zeid AA, Achmawy GA et al (2011) G2019S mutation of the leucine-rich repeat kinase 2 gene in a cohort of Egyptian patients with Parkinson\u2019s disease. Genet Test Mol Biomarkers 15:861\u2013866. https:\/\/doi.org\/10.1089\/gtmb.2011.0016","journal-title":"Genet Test Mol Biomarkers"},{"key":"2688_CR32","doi-asserted-by":"publisher","unstructured":"Qin L, Jing X, Qiu Z, et al (2016) Aging of immune system: immune signature from peripheral blood lymphocyte subsets in 1068 healthy adults. Aging (Albany NY) 8:848\u2013859. https:\/\/doi.org\/10.18632\/aging.100894","DOI":"10.18632\/aging.100894"},{"key":"2688_CR33","doi-asserted-by":"publisher","first-page":"278","DOI":"10.2174\/157015911795596612","volume":"9","author":"FR Buttarelli","year":"2011","unstructured":"Buttarelli FR, Fanciulli A, Pellicano C, Pontieri FE (2011) The dopaminergic system in peripheral blood lymphocytes: from physiology to pharmacology and potential applications to neuropsychiatric disorders. Curr Neuropharmacol 9:278\u2013288. https:\/\/doi.org\/10.2174\/157015911795596612","journal-title":"Curr Neuropharmacol"},{"key":"2688_CR34","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2-\u0394\u0394CT method. Methods 25:402\u2013408. https:\/\/doi.org\/10.1006\/meth.2001.1262","journal-title":"Methods"},{"key":"2688_CR35","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1515\/cclm-2016-0340","volume":"55","author":"G Polo","year":"2017","unstructured":"Polo G, Burlina AP, Kolamunnage TB et al (2017) Diagnosis of sphingolipidoses: a new simultaneous measurement of lysosphingolipids by LC-MS\/MS. Clin Chem Lab Med 55:403\u2013414. https:\/\/doi.org\/10.1515\/cclm-2016-0340","journal-title":"Clin Chem Lab Med"},{"key":"2688_CR36","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1134\/S1990519X19020081","volume":"13","author":"MA Nikolaev","year":"2019","unstructured":"Nikolaev MA, Kopytova AE, Baidakova GV et al (2019) Human peripheral blood macrophages as a model for studying glucocerebrosidase dysfunction. Cell Tissue Biol 13:100\u2013106. https:\/\/doi.org\/10.1134\/S1990519X19020081","journal-title":"Cell Tissue Biol"},{"key":"2688_CR37","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cca.2019.03.009","volume":"494","author":"W-L Chuang","year":"2019","unstructured":"Chuang W-L, Pacheco J, Hoxha D et al (2019) Galactosylsphingosine does not interfere with the quantitation of plasma glucosylsphingosine levels in Gaucher patients. Clin Chim Acta 494:48\u201351. https:\/\/doi.org\/10.1016\/j.cca.2019.03.009","journal-title":"Clin Chim Acta"},{"key":"2688_CR38","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/0-306-46826-3_33","volume":"477","author":"M Heinrich","year":"2000","unstructured":"Heinrich M, Wickel M, Winoto-Morbach S et al (2000) Ceramide as an activator lipid of cathepsin D. Adv Exp Med Biol 477:305\u2013315. https:\/\/doi.org\/10.1007\/0-306-46826-3_33","journal-title":"Adv Exp Med Biol"},{"key":"2688_CR39","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.neurobiolaging.2018.02.028","volume":"67","author":"PJ Hallett","year":"2018","unstructured":"Hallett PJ, Huebecker M, Brekk OR et al (2018) Glycosphingolipid levels and glucocerebrosidase activity are altered in normal aging of the mouse brain. Neurobiol Aging 67:189\u2013200. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2018.02.028","journal-title":"Neurobiol Aging"},{"key":"2688_CR40","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/humu.20676","volume":"29","author":"KS Hruska","year":"2008","unstructured":"Hruska KS, LaMarca ME, Scott CR, Sidransky E (2008) Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat 29:567\u2013583. https:\/\/doi.org\/10.1002\/humu.20676","journal-title":"Hum Mutat"},{"key":"2688_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms20123033","volume":"20","author":"N Hurvitz","year":"2019","unstructured":"Hurvitz N, Dinur T, Cohen MB et al (2019) Glucosylsphingosine (Lyso-gb1) as a biomarker for monitoring treated and untreated children with Gaucher disease. Int J Mol Sci 20:1\u20139. https:\/\/doi.org\/10.3390\/ijms20123033","journal-title":"Int J Mol Sci"},{"key":"2688_CR42","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1093\/brain\/awv179","volume":"138","author":"RN Alcalay","year":"2015","unstructured":"Alcalay RN, Levy OA, Waters CC et al (2015) Glucocerebrosidase activity in Parkinson\u2019s disease with and without GBA mutations. Brain 138:2648\u20132658. https:\/\/doi.org\/10.1093\/brain\/awv179","journal-title":"Brain"},{"key":"2688_CR43","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1007\/s11064-011-0516-0","volume":"36","author":"G Wu","year":"2011","unstructured":"Wu G, Huang J, Feng X et al (2011) Decreased expression of lysosomal alpha-Galactosiase A gene in sporadic Parkinson\u2019s disease. Neurochem Res 36:1939\u20131944. https:\/\/doi.org\/10.1007\/s11064-011-0516-0","journal-title":"Neurochem Res"},{"key":"2688_CR44","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jns.2008.04.011","volume":"271","author":"G Wu","year":"2008","unstructured":"Wu G, Yan B, Wang X et al (2008) Decreased activities of lysosomal acid alpha-D-galactosidase A in the leukocytes of sporadic Parkinson\u2019s disease. J Neurol Sci 271:168\u2013173. https:\/\/doi.org\/10.1016\/j.jns.2008.04.011","journal-title":"J Neurol Sci"},{"key":"2688_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-019-0339-z","volume":"14","author":"M Huebecker","year":"2019","unstructured":"Huebecker M, Moloney EB, Van Der Spoel AC et al (2019) Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson\u2019s disease. Mol Neurodegener 14:1\u201321. https:\/\/doi.org\/10.1186\/s13024-019-0339-z","journal-title":"Mol Neurodegener"},{"key":"2688_CR46","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.nbd.2017.11.006","volume":"110","author":"MP Nelson","year":"2018","unstructured":"Nelson MP, Boutin M, Tse TE et al (2018) The lysosomal enzyme alpha-Galactosidase A is deficient in Parkinson\u2019s disease brain in association with the pathologic accumulation of alpha-synuclein. Neurobiol Dis 110:68\u201381. https:\/\/doi.org\/10.1016\/j.nbd.2017.11.006","journal-title":"Neurobiol Dis"},{"key":"2688_CR47","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.tem.2018.11.003","volume":"30","author":"G Lin","year":"2019","unstructured":"Lin G, Wang L, Marcogliese PC, Bellen HJ (2019) Sphingolipids in the pathogenesis of Parkinson\u2019s disease and Parkinsonism. Trends Endocrinol Metab 30:106\u2013117. https:\/\/doi.org\/10.1016\/j.tem.2018.11.003","journal-title":"Trends Endocrinol Metab"},{"key":"2688_CR48","doi-asserted-by":"publisher","first-page":"6640","DOI":"10.1093\/hmg\/ddv369","volume":"24","author":"M Keatinge","year":"2015","unstructured":"Keatinge M, Bui H, Menke A et al (2015) Glucocerebrosidase 1 deficient Danio rerio mirror key pathological aspects of human Gaucher disease and provide evidence of early microglial activation preceding alpha-synuclein-independent neuronal cell death. Hum Mol Genet 24:6640\u20136652. https:\/\/doi.org\/10.1093\/hmg\/ddv369","journal-title":"Hum Mol Genet"},{"key":"2688_CR49","doi-asserted-by":"publisher","unstructured":"Mao C yuan, Yang J, Wang H, et al (2017) SMPD1 variants in Chinese Han patients with sporadic Parkinson\u2019s disease. Park Relat Disord 34:59\u201361. https:\/\/doi.org\/10.1016\/j.parkreldis.2016.10.014","DOI":"10.1016\/j.parkreldis.2016.10.014"},{"key":"2688_CR50","doi-asserted-by":"crossref","unstructured":"Emelyanov A, Usenko T, Nikolaev M, et al. Increased alpha-synuclein level in CD45+ blood cells in asymptomatic carriers of GBA mutations. Mov Disorders. 2021, accepted.","DOI":"10.1002\/mds.28688"},{"key":"2688_CR51","doi-asserted-by":"crossref","unstructured":"Zhuravlev A, Lavrinova A, Kulabuhova D, et al. The CD45+ blood cells alpha-synuclein concentration in synucleinopathies. Eur Neuropsychopharmacol Supp. 2021, accepted.","DOI":"10.1016\/j.euroneuro.2021.10.812"},{"key":"2688_CR52","unstructured":"Keatinge M, Gegg ME, Watson L, Mortiboys H (2020) Unexpected opposing biological effect of genetics risk factors for Parkinson \u2019 s disease ( Condensed title\u202f: ASM inhibition rescues GCase deficiency ). 1\u201328"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-021-02688-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-021-02688-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-021-02688-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T04:06:45Z","timestamp":1700107605000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-021-02688-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,23]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["2688"],"URL":"https:\/\/doi.org\/10.1007\/s12035-021-02688-0","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,23]]},"assertion":[{"value":"7 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by ethics committee of Pavlov First Saint-Petersburg State Medical University.Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}